Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results

por Weinblatt, Michael E., Baranauskaite, Asta, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Baek, Inyoung, Ghil, Jeehoon
Publicado 2018

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

por Fleischmann, Roy M., Alten, Rieke, Pileckyte, Margarita, Lobello, Kasia, Hua, Steven Y., Cronenberger, Carol, Alvarez, Daniel, Bock, Amy E., Sewell, K. Lea
Publicado 2018

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

por Weinblatt, Michael E., Baranauskaite, Asta, Niebrzydowski, Jaroslaw, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Cheong, Soo Yeon, Ghil, Jeehoon, Sokolovic, S., Mekic, M., Prodanovic, N., Gajic, B., Karaselimovic‐Dzambasovic, E., Pojskic, B., Toncheva, A., Dimitar, P., Rodina, L., Geneva‐Popova, M., Staykov, I., Stoilov, R., Podrazilova, L., Mosterova, Z., Simkova, G., Kopackova, J., Stejfova, Z., Vencovsky, J., Urbanova, Z., Janska, L., Galatíkova, D., Stropuviene, S., Sniuoliene, I., Sitek‐Ziolkowska, K., Rell‐Bakalarska, M., Kolasa, R., Daniluk, S., Sliwowska, B., Bartosik‐Twardowska, M., Brzezicki, J., Konieczny, M., Jeka, S., Choe, J., Bae, S., Kang, Y., Prystupa, L., Vyacheslav, Z., Gasanov, I., Yatsyshyn, R., Rekalov, D., Iaremenko, O., Stanislavchuk, M., Tseluyko, V.
Publicado 2017